If there was any doubt that Namaste Technologies (OTCMKTS:NXTTF, CNSX:N) is on the right track and can do what it set out to do, it was just wiped away today. Per this morning’s press release, the company proved it’s going to be able to reach its near-term revenue target by tweaking its recently-acquired properties. Investors who’ve been kicking the tires with NXTTF — or with N, for Canadian investors — the time to act is arguably sooner than later.
Namaste Technologies sells electronic vaporizers, which are more commonly categorized as electronic cigarettes (or e-cigs). Though initially intended as a means of avoiding tobacco smoke without giving up nicotine, it was only a matter of time before the idea was adapted and new technologies were developed to vaporize whatever it is people choose to smoke. Marijuana was an obvious good-fit candidate for the idea, and Namaste Technologies is simply capitalizing on that growing opportunity. The end result: Namaste now operates more than 30 e-commerce retail stores with monthly traffic of over 550,000 visitors…
… or did anyway. As of this morning, In terms of total traffic, Namaste has increased its total pre-acquisition monthly traffic from 42,353 in July to 596,453 in November, an overall increase of 1,308.3% in monthly traffic. That’s a pretty big leap forward in not a lot of time, which is part of what makes the Namaste Technologies opportunity so compelling.
It takes a closer look at the numbers and a clear understanding of what Namaste bought and when it bought it to fully appreciate how big of a deal the news is.
As was noted back in the November 10th newsletter:
best shares to invest in: LeMaitre Vascular, Inc.(LMAT)
- [By Lisa Levin]
In trading on Thursday, healthcare shares rose by just 0.6 percent. Meanwhile, top losers in the sector included LeMaitre Vascular Inc (NASDAQ: LMAT), down 5 percent, and pSivida Corp. (NASDAQ: PSDV), down 3 percent.
- [By Monica Gerson]
The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:
best shares to invest in: TravelCenters of America LLC(TA)
- [By Lisa Levin]
In trading on Monday, energy shares dipped by 0.70 percent. Meanwhile, top losers in the sector included TravelCenters of America LLC (NYSE: TA), down 18 percent, and Alon USA Energy, Inc. (NYSE: ALJ), down 8 percent.
best shares to invest in: Nektar Therapeutics(NKTR)
- [By Lisa Levin]
Shares of Nektar Therapeutics (NASDAQ: NKTR) got a boost, shooting up 38 percent to $21.33 after the company reported that it has met its primary and secondary endpoints in Phase 3 Summit-07 study for chronic pain.
- [By Ben Levisohn]
Nektar Therapeutics (NKTR) has soared 21% to $18.80 after positive results from a pain-killer trial.
Tiffany (TIF) has gained 1.6% to $93.90 after getting upgraded to Outperform from Market Perform at William Blair.
- [By Sean Williams]
Shares of Nektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company that utilizes its proprietary intellectual property via licensing deals and through collaborations in the clinical development process to help fight cancer, autoimmune diseases, and chronic pain, surged as much as 20% on Thursday after the company reported its fourth-quarter and full-year results after the closing bell on Wednesday.
- [By Todd Campbell]
Nektar Therapeutics (NASDAQ:NKTR) is an intriguing commercial-stage biotech company that’s just reported positive late-stage trial results for its pain-busting drug NKTR-181. However, shares have jumped on the news, and the company’s market cap has swollen to more than $3 billion. Is there more running room left for its investors?
best shares to invest in: Brookline Bancorp Inc.(BRKL)
- [By Dividends4Life]
Memberships and Peers: PBCT is a member of the S&P 500 and a member of the Broad Dividend Achievers Index. The company’s peer group includes: Bank of America Corporation (BAC) with a 0.3% yield, Brookline Bancorp, Inc. (BRKL) with a 3.7% yield and Westfield Financial Inc. (WFD) with a 3.5% yield.
best shares to invest in: Cytokinetics, Incorporated(CYTK)
- [By Lisa Levin]
Cytokinetics, Inc. (NASDAQ: CYTK) shares dropped 27 percent to $8.12 on the back of negative trial results for its amyotrophic lateral sclerosis, or ALS, treatment candidate tirasemtiv in a late-stage study. The results of the international Phase 3 study showed tiraemtive did not meet the primary endpoint of change from baseline in slow vital capacity, or SVS, evaluated at 24 weeks, as well the secondary endpoints evaluated at 48 weeks.
- [By Paul Ausick]
Cytokinetics Inc. (NASDAQ: CYTK) dropped about 37% Tuesday to post a new 52-week low of $7.00 after closing at $11.10 on Monday. The 52-week high is $17.20. Volume was around 7 million, about 14 times the daily average of less than 500,000. The company’s ALS drug failed ti meet its endpoint in a phase 3 study.
- [By Chris Lange]
Cytokinetics, Inc. (NASDAQ: CYTK) saw its shares take a massive step back in Tuesdays session after the firm reported negative results for its trial in amyotrophic lateral sclerosis (ALS). Specifically, the firms Phase 3 clinical trial of tirasemtiv did not meet the primary endpoint or any of the secondary endpoints.